Novavax-GE/Avimex Pact Interest (NVAX)

Posted in pre-market 
October 20th, 2009

Novavax, Inc. (NASDAQ: NVAX) is trading higher after it announced that it began a two-stage clinical study of its virus-like particle H1N1 influenza vaccine in Mexico.  This is in collaboration with Avimex Laboratories and GE Healthcare. Shares were indicated up around 9% in early trading, but at 8:20 AM EST we have seen some 400,000 shares trade hands and the last print was up almost 7% at $4.01.  Average volume is now 8 million shares and this one feels like it is petering out at least a bit in the volume.  The 52-week trading range is $0.52 to $7.79 and the market cap before today’s jump was $340.5 million.   -JON OGG

Comments are closed